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Head and neck squamous cell carcinoma (HNSCC) is the 6th most common human
cancer and affects approximately 50,000 new patients every year in the US. The major
risk factors for HNSCC are tobacco and alcohol consumption as well as oncogenic HPV
infections. Despite advances in therapy, the overall survival rate for all-comers is only
50%. Understanding the biology of HNSCC is crucial to identifying new biomarkers,
implementing early diagnostic approaches and developing novel therapies. As in several
other cancers, HNSCC expresses elevated levels of MCT4, a member of the SLC16
family of monocarboxylate transporters. MCT4 is a H+-linked lactate transporter which
functions to facilitate lactate efflux from highly glycolytic cells. High MCT4 levels in
HNSCC have been associated with poor prognosis, but the role of MCT4 in the
development and progression of this cancer is still poorly understood. In this study,
we used 4-nitroquinoline-1-oxide (4NQO) to induce oral cancer in MCT4−/− and wild
type littermates, recapitulating the disease progression in humans. Histological analysis
of mouse tongues after 23 weeks of 4NQO treatment showed that MCT4−/− mice
developed significantly fewer and less extended invasive lesions than wild type. In mice,
as in human samples, MCT4 was not expressed in normal oral mucosa but was detected
in the transformed epithelium. In the 4NQO treated mice we detected MCT4 in foci of the
basal layer undergoing transformation, and progressively in areas of carcinoma in situ and
invasive carcinomas. Moreover, we found MCT4 positive macrophages within the tumor
and in the stroma surrounding the lesions in both human samples of HNSCC and in the
4NQO treated animals. The results of our studies showed that MCT4 could be used as
an early diagnostic biomarker of HNSCC. Our finding with the MCT4−/− mice suggest
MCT4 is a driver of progression to oral squamous cell cancer and MCT4 inhibitors could
have clinical benefits for preventing invasive HNSCC.
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INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is the 6th
most common human cancer with almost 50,000 new cases
diagnosed in the United States each year (1, 2). Among the
different subtypes of HNSCC, oral squamous cell carcinoma
(OSCC), especially of the tongue, is the most common. Risk
factors for OSCC are tobacco use and alcohol consumption (3, 4).
The high mortality with HNSCC and OSCC in particular, with
a 5-year survival rate of only 50%, creates an urgent need for
better understanding of disease biology as well as prognostic and
predictive biomarkers and novel therapies.
Recent studies have shown that, similar to other types of
cancer, an increase in monocarboxylate transporter 4 (MCT4)
expression in patients with OSCC correlates with a poor
outcome (5–8). MCT4 is a member of the SLC16 family of
solute transporters and functions as a proton-coupled lactate
transporter (9). MCT4 is primarily expressed in glycolytic
cells including fast twitch muscle, neural retina and activated
macrophages where it facilitates the eﬄux of lactate (10–12).
Warburg was the first to show that cancer cells often exhibit
a high rate of aerobic glycolysis producing large amounts of
lactate. In tumors, high levels of lactate are generated by
a subset of highly glycolytic cancer and stromal cells. It is
then taken up and oxidized by other tumor cells expressing
high levels of monocarboxylate transporter 1 (MCT1), another
member of the SLC16 family (13). Lactate is metabolized through
oxidative phosphorylation to produce ATP and intermediates
that support tumor growth. In addition to its role as metabolic
substrate, lactate is also a signaling molecule with important
roles in angiogenesis, tumor migration and invasion, as well as
modulation of the immune system (14).
The experimental models currently available for
understanding the contribution of MCTs and lactate to the
progression of cancer are based on the manipulation of
gene expression in cancer cell lines for in vitro and in vivo
studies (15–17). These studies have contributed to a greater
understanding of the role of lactate in tumor progression and
survival, highlighting the therapeutic potential of targeting
MCT1 and MCT4. However, the importance of epithelial and
stromal MCT4 in driving cancer progression remains poorly
understood.
In this study we investigated the role of MCT4 in the
progression of OSCC in a well-established model of oral
squamous cell carcinoma using the carcinogen 4-nitroquinoline-
1-oxide (4NQO) (18) in wild type (MCT4+/+) and MCT4
knockout (MCT4−/−) mice. After exposure to 4NQO, MCT4
knockout animals developed significantly fewer and less
extensive invasive SCC lesions compared to wild type mice.
Importantly, MCT4, which is typically absent in normal
tongue epithelium, was expressed early in regions of dysplastic
epithelium and later in areas of in situ carcinomas (CIS) and
invasive squamous cell carcinomas (SCC). In addition, MCT4
was detected in macrophages within the lesion and adjacent
stroma after 4NQO exposure, similar to what is observed in
human OSCC samples. Our results suggest that MCT4 is critical
for the progression from dysplastic lesions to invasive cancer
and is therefore a relevant therapeutic target for the treatment
of OSCC.
MATERIALS AND METHODS
Human Study
This study was approved by the institutional review board (IRB)
at Thomas Jefferson University. Samples of primary tumors
from 9 patients with head and neck cancer were obtained
from archived paraffin-embedded tissue blocks for histological
analysis. Patient data were collected, including: age, sex, tobacco
use, stage of disease, location of tumor, and histological features.
Animals
MCT4+/− mice were purchased from Taconic Bioscience. The
animals were backcrossed for 10 generations to C57Bl/6N
(Taconic) mice and MCT4+/− mice were used for breeding
to obtain knock out and wild type littermates. Genotype was
confirmed by PCR.Mice were kept in a 12:12 light/dark cycle and
provided with ad libitum food and drinking water.
Mouse Oral Carcinogenesis Induction
MCT4−/− and wild type mice (n = 15–16) 12 weeks of age,
were treated with 4-nitroquinoline-1-oxide (4NQO; cat # N8141,
Sigma-Aldrich) in the drinking water at a concentration of
50µg/ml. The animals were treated for 16 weeks with the
4NQO and then for an additional 7 weeks with water only.
Fresh 4NQO/water was supplied every week. Animals were
sacrificed after 14 weeks of treatment and at 23 weeks or
when body weight loss was >20% of original weight. Oral
cavities were inspected weekly for signs of lesions, and body
weight was monitored as a sign of distress. All the experiments
were conducted in accordance and with the approval of the
Institutional Animal Care and Use Committee (IACUC) at
Thomas Jefferson University.
Antibodies
The following antibodies were used: MCT4 (SLC16A3) 19-mer
peptide sequence CKAEPEKNGEVVHTPETSV-cooh affinity
purified rabbit antibody and MCT1 (SLC16A1) 19-mer peptide
sequence CSPDQKDTEGGPKEEESPV-cooh affinity purified
rabbit antibodies were generated by YenZym Antibodies, South
San Francisco, CA. (11). Mouse anti-human MCT4 (D-1)
antibody was from Santa Cruz Biotechnology. Rabbit anti
human- CD163 was from Abcam. Rat anti-mouse F4/80 (CI-A3-
1) was fromNovus Biologicals. CD45.2 (clone 104), PD-L1 (clone
10F.9G2), Ly6C (clone HK1.4), Ly6G (clone 1A8), CD11b (clone
M1/70) were from BioLegend.
Analysis of Human Dual Labeling for
CD163-Positive Macrophages and MCT4
Paraffin sections of human HNSCC were dual labeled by
immunohistochemistry as detailed below with CD163 (Abcam)
developed in red/pink and MCT4 (Santa Cruz Biotechnology)
developed in brown. Slides were scanned at low power (4x)
and 3 areas containing cancer cells and identifiable macrophages
(stained in red/pink) that were within tumor nests or in the
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immediate adjacent stroma were selected and then scored at
high power (40x). Each 40x field was scored as positive when
>80% macrophages were also MCT4 positive. The same method
was used to evaluate normal, non-tumor areas within the same
section. These areas were located in stroma underlying normal
squamous epithelium or in areas of non-involved muscle.
Macroscopic Photography and Lesional
Area Quantification
Tongues were harvested and placed on ice in phosphate buffered
saline (PBS). Immediately prior to photography, individual
tongues were incubated for one minute in a solution of 10%
acetic acid and 4% ethanol followed by two PBS rinses [modified
from Mashberg et al. (19)]. This treatment accentuated lesional
areas from relatively unaffected areas. Images were captured with
AxioVision LE software using a 5megapixel Zeiss AxioCam Erc5s
color camera coupled to a Stemi 2000C Zeiss stereomicroscope at
0.65xmagnification. ImageJ was used for the quantification of the
affected areas on the dorsal surface of the tongue. Briefly, lesional
areas which were identified as white opaque raised regions,
were measured and the average percentage lesional area was
calculated for wild type versus MCT4−/− tongues. The images
were evaluated in a blinded manner by 2 independent observers.
Tissue Collection and Histopathological
Analysis
Tongue samples were fixed in 10% formalin and then cut
lengthwise into 3 pieces and embedded separately in paraffin.
Four micron sections were cut from all blocks and stained with
hematoxylin and eosin (H&E) for histopathological evaluation
by an expert in oral cancer pathology, to determine presence of
carcinoma-in-situ and invasive carcinoma. In other experiments,
tongues samples were cut lengthwise and either flash frozen
in liquid nitrogen or embedded in OCT compound for frozen
sectioning.
Immunohistochemistry of Paraffin and
Frozen Sections
A 3-step avidin-biotin horseradish peroxidase method was used
for single antibody labeling on paraffin sections as previously
described (20). Briefly after deparaffinization and rehydration of
the sections, antigen retrieval was performed in 0.01M citrate
buffer, pH 6.0 using an electric pressure cooker. An avidin-biotin
kit (Biocare Medical) was used to block endogenous biotin and
the sections were blocked with 10% goat serum (Vector Labs) in
PBS at 4◦C. Primary antibody was incubated for 1 hour followed
by biotinylated species-specific secondary antibody (Vector Labs)
and avidin-biotin-horseradish peroxidase complex (ABC Elite
Kit, Vector Labs) with washing in PBS between steps. Antibody
binding was detected with 3,3′ diaminobenzidine (DAB liquid
substrate kit, Agilent Technologies). A similar procedure was
used for frozen sections that were fixed in acetone. For dual
antibody labeling, a 2-step procedure was used as described in
(21). Briefly, after antigen retrieval and blocking in 5% BSA,
sections were incubated simultaneously with primary antibodies
followed species-specific secondary antibodies conjugated with
alkaline phosphatase or peroxidase (Jackson ImmunoResearch).
Antibody binding was detected using DAB liquid substrate kit
and ImmPACT Vector Red substrate kit (Vector) containing
1.25mM levamisole (Sigma-Aldrich). Light microscopy images
were captured using cellSens Entry software and the Olympus
DP22 camera attached to an Olympus CX41 microscope
(Olympus Scientific Solutions Americas).
Dual Labeling by Immunofluorescence
For mouse samples double labeling immunofluorescence was
performed using frozen sections after fixation in acetone
and blocking in 5% BSA. Primary antibodies were incubated
together for one hour at RT, washed and detected with
AlexaFluor 488 conjugated donkey anti-rat IgG and AlexaFluor
568 conjugated goat anti-rabbit IgG (ThermoFisher Scientific).
Nuclei were stained with DAPI and sections were mounted
with ProLong Gold anti-fade (ThermoFisher Scientific). All
immunofluorescent labeling images were captured on the Nikon
A1R confocal microscope with a 40x oil objective lens with or
without 2x zoom.
Macrophage Quantification in
4NQO-Treated Mice
Macrophages were identified by immunohistochemistry using
the F4/80 antibody in frozen tissue sections at 14 and 23 weeks.
Areas of involved and non-involved epithelia were identified by
a pathologist with expertise in head and neck pathology, and 3–5
digital images were taken at 20×magnification and analyzed with
Image J software calibrated for magnification. The subepithelial
stromal area for each image was measured and the number of
F4/80 positive cells was counted within each area. The number of
F4/80 positive cells per cubic micron was calculated and adjusted
per mm3 and the average number for involved and non-involved
areas were generated for wild type and knockout samples.
Implantable Tumor Models
TC-1 cells (kindly provided by Dr. Ulrich Rodeck) were
maintained in RPMI (Corning Life Science) with 1% PenStrep
(Gemini Bio-Products) and 10% fetal bovine serum (Benchmark
serum, Gemini Bio-Products). TC-1 cells are HPV transformed
C57Bl/6 lung epithelium cells (22). For the transplantable tumor
model, TC-1 cells were implanted subcutaneously in the shaved
right flank of 10-12 week old MCT4−/− and control littermates.
1 × 105 TC-1 cells were injected in 100uL PBS. Tumor area was
calculated using the length and width of the tumor (in mm2),
which was measured using digital calipers. For growth curve
studies, animals were sacrificed after 25 days from implantation
when the tumor was growing exponentially.
Blood Collection and Flow Cytometry
Approximately 80 µL of blood was collected in a tube containing
12 µL heparin from the retro-orbital sinus. 40 uL of the
collected blood was stained using Zombie Aqua Fixable Viability
Kit (BioLegend) and antibodies specific for the monocyte
population. Following staining, red blood cell lysis buffer
(150 mmol/l NH4Cl, 10 mmol/l NaHCO) was added to the
samples to isolate leukocytes. CountBright absolute counting
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FIGURE 1 | MCT4 is expressed in Human OSCC: Single MCT4 (A,B) and dual MCT4/CD163 (C–E) immunostaining in paraffin embedded samples of human OSCC.
Area of adjacent normal epithelium in OSCC sample #1 (A), area of squamous cell carcinoma within the same sample #1 (B). MCT4 negative/CD163 positive
macrophages in adjacent normal area of oral mucosa in sample #2 (C). MCT4 positive/CD163 positive macrophages in areas of cancer cells within same sample #2
(D). Boxed region in D is showed at higher magnification in E (2.5X). Scale bar: 20µm. S, stroma; E, epithelium.
beads (ThermoFisher Scientific) were added to the samples
immediately prior to analysis. Samples were run on the BD
LSRFortessa flow cytometer (BD Biosciences) and data was
analyzed using FlowJo Version 10.1 (Treestar).
Western Blot Analysis
Cells and tissues were lysed in RIPA buffer (ThermoFisher
Scientific) containing protease inhibitor cocktail (ThermoFisher
Scientific). Samples were centrifuged and supernatant collected
for protein analysis. After protein quantification with the
BCA method, samples were separated using Bis-Tris NuPage
precast gels (ThermoFisher Scientific) and transferred to PVDF
membranes. After blocking with 5% nonfat milk for 1 hour,
primary antibodies were incubated overnight at 4◦C.Membranes
were washed in TBS-tween buffer and incubated in HRP
conjugated secondary antibodies for 1h at room temperature.
Blots were developed using SuperSignalWest Dura ECL substrate
(ThermoFisher Scientific) and imaged using FluorChem M
ProteinSimple imager.
Data Analysis
All data are presented as mean ± standard error. Data were
analyzed with GraphPad Prism v7 (GraphPad software) or R
v3.5.0 (R-project.org). Unless specified differently, two-tailed-t
test or ANOVA were performed to analyze the mean difference
between groups. For correlation analysis Fisher’s exact test was
used. Data reported in Figure 6M data were analyzed using a
robust linear mixed effect model with random effect of mice and
fixed effect of time, genotype and area. Statistical significance was
defined as p-value < 0.05.
RESULTS
MCT4 Expression in Human Oral
Squamous Cell Carcinoma
MCT4 is expressed in both cancer cell and stromal compartments
in human OSCC and is typically not present in normal
squamous epithelia (Figures 1A,B). In the present study, MCT4
expression was further evaluated in macrophages identified by
the marker CD163 in nine cases of HNSCC. The demographic
and pathological characteristics of these cases are summarized
in Table 1. Paraffin sections were labeled with antibodies to
CD163 and MCT4 simultaneously (Figures 1C–E) and the
percentage of macrophages positive for MCT4 was evaluated
in a blinded fashion by two independent observers (Table 2).
CD163-positive macrophages within cancer cell nests or in
the immediate adjacent stroma were evaluated at high power
and compared to macrophages in normal or non-involved or
control areas distant from cancer cell sites. MCT4 staining in
macrophages was scored as positive in fields that contained
80% or greater double positive cells. Six of nine cases had
macrophages positive for CD163 that were also positive
for MCT4 (66.7%). When CD163-positive macrophages were
evaluated in non-involved or control areas that were distant and
free from the presence of cancer cells, all cases were negative
(p < 0.01).
MCT4−/− Mouse Model for Oral Carcinoma
Development
Based on the strong correlation between MCT4 expression and
poor outcomes in OSCC we wanted to develop an in vivo animal
model to test whether MCT4 was a marker or a driver of
aggressive cancer. MCT4+/− mice were purchased from Taconic
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TABLE 1 | Demographics and Pathologic characteristics.
Mean age (range) 64.9 (50–82)
Gender 6 male/3 females
Tobacco use (>10 pack/year) 6 (67%)
p16 positive 1 (11%)
SUBSITE
Oral cavity 7 (78%)
Oral tongue 2
Floor of mouth 3
Gingiva 2
Oropharynx 2 (22%)
Base of tongue 1
Tonsil 1
T STAGE
T1 1 (1%)
T2 3 (33%)
T4a 5 (56%)
N STAGE
N0 5 (56%)
N2b 3 (33%)
N2c 1 (11%)
PATHOLOGICAL MARKERS
ECE 2 (22%)
Positive margins 2 (22%)
PNI 4 (44%)
LVI 2 (22%)
DIFFERENTIATION
Well 0
Moderate 8 (89%)
Poor 1 (11%)
TABLE 2 | HNSCC MCT4 Expression in CD163-positive macrophages.
Site MCT-4 Positive MCT-4 Negative Total
Tumor 6 3 9
Control 0 8 8
Total 6 11 17
Number of samples with CD163 stained macrophages positive or negative for MCT4 in
human HNSCC (n= 9). Tumor site is intra-tumoral or immediate peri-tumoral area; Control
is adjacent non-tumor i.e., subepithelial stroma or non-involved muscle; Positive is >80%
dual positive within field.
Biosciences and backcrossed to homozygosity, on a C57BL6/N
background. No changes in breeding or growth were observed in
these mice. Figure 2A is a representative Western blot showing
that MCT4 was detected in lysates from retina, skeletal muscle
and activated macrophages from wild type but not in MCT4−/−
mice (Figure 2A). Frozen sections of wild type and MCT4−/−
tongues from animals not exposed to 4NQO were labeled with
MCT4 antibody. MCT4 was not present in the mucosa but
was detected in the sarcolemma of the skeletal muscle fibers
(Figures 2B,C). This pattern of MCT4 expression was identical
to that of human oral mucosa (Figure 1A).
Administration of 4NQO Induces More
Aggressive Oral Squamous Carcinoma in
Wild Type Animals
Treatment of mice with 4NQO in the drinking water is a well-
established model for induction of OSCC (23). To understand
the contribution of MCT4 to the development and progression
of oral squamous cell carcinoma (OSCC), MCT4−/− mice and
control littermates were treated for 16 weeks with 50µg/ml
4NQO in the drinking water, followed by 7 weeks of pure
water (Figure 3A). After 23 weeks of treatment, the animals
were euthanized and the tongues excised and assessed for
cancerous lesions as described in materials and methods. As
reported in other studies using 4NQO, during the treatment
with the carcinogen the mice lost up to 20% of the initial
body weight, but the change was not significantly different
between the wild type and the MCT4−/− group. Macroscopic
examination of the tongues showed that wild type animals
developed more prominent and numerous lesions compared to
MCT4−/− animals (Figures 3B,C). Quantification of the area
occupied by the white lesions on the dorsal surface of the tongues
showed that the wild type animals had 39% of the surface
covered by lesions while the MCT4−/− animals had only 25%
(p < 0.05) (Figure 3D). The tongues of the 23 week 4NQO
treated wild type and MCT4−/− mice were paraffin embedded
and sectioned. Microscopic observation of H&E-stained sections
revealed epithelial changes that ranged from mild to severe
dysplasia and carcinoma in situ (CIS; Figures 3E,F,I,J) to invasive
oral squamous cell carcinoma (OSCC; Figures 3G,H,K,L). There
was nuclear enlargement and hyperchromasia that was restricted
to the basal layer in areas of mild dysplasia as well as
cytologic atypia that involved the entire epithelial thickness,
with associated acanthosis and hyperparakeratosis in areas of
severe dysplasia and CIS (Figure 3). All animals showed evidence
of CIS, however, in MCT4−/− the pathological features of
CIS were qualitatively less pronounced, with fewer areas of
epithelial involvement (Figures 3E,F,I,J). MCT4−/− mice had
fewer invasive lesions (>1mm depth of invasion), with 2 of
12 knockout mice (16.7%) having invasive SCC compared to 8
of 13 wild type animals with invasive SCC (61.5%; p < 0.05)
(Figures 3G,H,K,L). However, MCT4−/− mice did show limited
micro-invasive features with involvement of less than 1mm
depth in 4 of 12 animals (33.3%), compared to 2 of 13 wild
type animals (15.4%) but this was not statistically significantly
different. The number of CIS, invasive SCC and micro-invasive
SCC are summarized in Table 3.
MCT4 Is Expressed at an Early Stage of
Disease
4NQO treated animals developed a complex range of changes
in the epithelium that allowed us to study changes in MCT4
expression during the tumorigenic process. To understand the
importance of MCT4 in the development of oral cancer, we
sacrificed the animals after 14 weeks of 4NQO treatment when
early visible changes could be identified on the surface of the
tongues (24). Immunohistochemistry of frozen section of the
tongues was performed with MCT4 antibody. Focal expression
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FIGURE 2 | Characterization of MCT4−/− animals. Western blot of detergent lysates prepared from retinas, extensor digitorum longus (EDL) muscle, and LPS
activated bone marrow derived macrophages (BMDM) from wild type (+/+) and MCT4 knock out (-/-) mice (A). Frozen sections of mouse tongue from MCT4 (+/+)
(B) and MCT4−/− (C) mice labeled with MCT4 antibody. Ep, epithelium; SkM, skeletal muscle. Scale bar, 50µm.
of MCT4 was detected in the epithelial cells of the stratum basalis
as well as in small foci extending into the stratum spinosum
(Figures 4A–D). Additionally, in areas where there was epithelial
MCT4 expression, we also detected an increase in MCT4 positive
cells in the adjacent stroma (Figure 4B). Immunostaining of
frozen sections of tongue tissues after 23 weeks showed that
with progression of OSCC, the expression of MCT4 persisted
and was primarily detected in foci within the upper layers of
the epithelium (Figures 4E,F) and often in CIS lesions having
a papillary morphology (papillary carcinoma in-situ). In regions
of invasive cancer, MCT4 was detected in a more widespread
pattern throughout the tumor (Figures 4G,H) and was present
on transformed epithelial cells and also in adjacent stromal cells
within lesional areas.
Increased Expression of MCT1 in OSCC in
Wild Type and MCT4 Knock Out Mice
We investigated the expression of MCT1 in wild type and
MCT4−/− mice. In tongues from wild type and MCT4−/−
untreated mice, MCT1 was primarily restricted to the stratum
basalis with faint labeling in the lower layers of the stratum
spinosum (Figures 5A,E). This pattern of expression also
parallels the MCT1 expression observed in normal human
oral squamous epithelium (5, 25). Note that skeletal muscle
fibers stain positively for MCT1 as shown in the figure
and serve as a positive control. After 4NQO treatment, the
expression of MCT1 increased in focal dysplastic areas of
the tongues of both wild type and MCT4−/− animals and
could be detected in the upper layers of the epithelium
(Figures 5B,F). However, in the more aggressive invasive
SCC lesions, MCT1 expression became irregular and was
confined to groups of cells with an epithelial morphology
(Figures 5C,D,G,H). Overall the changes in MCT1 expression
patterns were similar in both wild type and MCT4−/−
tongues and was not consistent with any compensatory
expression due to the absence of MCT4 in MCT4−/−
mice.
MCT4 Positive Macrophages Are Present
in the Stroma
In the human OSCC, MCT4 positive macrophages were found
within the lesions and in the adjacent stroma. Therefore, we
investigated the presence of MCT4 positive macrophages in the
4NQO treated animals. Macrophages identified by F4/80 were
positive for MCT4 in wild type mice at both 14 weeks (data not
shown) and 23 weeks (Figures 6A–C). While F4/80 positive cells
were detected in the mucosa of MCT4−/− mice, they were not
co-labeled with MCT4 (Figures 6D–F). To determine whether
there was a difference in macrophage number between wild
type and MCT4−/− mice, tongue sections from untreated, and
14 and 23 week 4NQO-treated mice were stained with F4/80
by immunohistochemistry (Figures 6G–L) and the number of
positive cells was quantified as described in Materials and
Methods. In normal untreated wild type and MCT4−/− tongues
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FIGURE 3 | Reduced invasive oral squamous cell carcinoma in MCT4−/− mice after 4NQO: Study design: 12 week old mice were treated for 16 weeks with 4NQO
(50µg/ml) in the drinking water, followed by 7 weeks of plain water. Mice were sacrificed after 14 weeks of treatment or at 23 weeks (A). Photographs of wild type
(B) and MCT4−/− (C) tongues after 23 weeks of treatment. Quantification of superficial lesions expressed as percentage of total dorsal tongue surface area (n = 8
per group), **p < 0.01 (D). Representative H&E stained paraffin sections of tongues from wild type and MCT4−/− animals treated with 4NQO and sacrificed at 23
weeks (E–L) CIS, carcinoma-in-situ; SCC, invasive squamous cell carcinoma. F, H, J and L are higher magnifications of E, G, I and K respectively. *Indicates invasive
SCC. Scale bar: 100µm (F,H,J, L) or 50µm (E,G,I,K).
the numbers of F4/80 positivemacrophages were not significantly
different (Figure 6M), with both groups having similar baseline
numbers of macrophages. After 14 weeks of 4NQO treatment
the number of macrophages present in the involved regions
(perilesional areas) of wild type animals was 23% greater than
in the MCT4−/− animals (p < 0.05). By 23 weeks, the number
of macrophages in the MCT4−/− affected areas was similar to
the wild type. We also evaluated the number of macrophages in
non-involved areas, (not lesional) and they were similar in both
wild type and MCT4−/− animals exposed to 4NQO, although
the numbers in the lesional areas were significantly increased
compared to the non-involved areas (average difference 35.3,
p < 0.03). This indicates that the increase in macrophages is
due to the presence of cancer cells and not because of a general
inflammatory response to the 4NQO.
We also analyzed the levels of circulating monocytes in
the 4NQO treated animals to determine if the differences in
TABLE 3 | Histological findings in 23 weeks 4NQO treated wild type and
MCT4−/− tongues.
wild type MCT4−/−
CIS 13 12
Micro invasive SCC 2 4
Invasive SCC 8 2
CIS, carcinoma in situ; SCC, squamous cell carcinoma.
macrophage number in the lesion was due to a defect in
recruitment and mobilization. The total number of monocytes
in circulation was higher in the untreated MCT4−/− animals,
but the difference was not statistically significant. At 23 weeks
after 4NQO treatment, the number of circulating monocytes in
the MCT4−/− animals was 2.6 times higher than the wild type
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FIGURE 4 | MCT4 is expressed at different stages of oral cancer. Frozen sections of tongues from 4NQO treated wild type mice. MCT4 staining is detected in the
basal and suprabasal epithelial layers and in the stroma (A, magnified in B), in papilloma (C, magnified in D) after 14 weeks of treatment; and in the upper squamous
epithelium of carcinoma in situ (E, magnified in F) and in both the epithelium and stroma of invasive cancer (G, magnified in H) at the 23 weeks timepoint. Scale bar:
100µm (A,C,E,G) or 20µm (B,D,F,H).
FIGURE 5 | MCT1 expression is altered in 4NQO treated wild type and MCT4−/− animals. IHC staining of paraffin sections of tongues from untreated and 23 weeks
4NQO treated wild type and MCT4−/− mice. MCT1 expression in normal tongue tissue is restricted to the basal cell layer of the epithelium in both wild type and
MCT4−/− mice (A,E). After 4NQO treatment, MCT1 extends into the suprabasal region of dysplastic lesions (B,F), and is irregularly expressed in areas at the leading
edge of invasive cancer (C,D,G,H). Scale bar: 50µm or 20µm (D,H).
(p< 0.05), suggesting a defect in the recruitment of macrophages
to the tumors.
MCT4 in Syngeneic Tumors Is Sufficient to
Drive Cancer Growth
To investigate the contribution of MCT4 expressed in tumor
stroma to the development and progression of the OSCC, TC-
1 cells, derived from C57Bl/6 lung carcinoma were implanted
into the flanks of MCT4−/− mice and control littermates.
Surprisingly the tumor growth was independent of the host
genotype with similar tumor sizes in wild type and MCT4−/−
animals (Figures 7A–B). Additionally, there was no difference
in the number of circulating monocytes between wild type
and MCT4−/− mice (Figure 7C). Since we were perplexed
by this finding we examined the expression of MCT1 and
MCT4 in TC-1 cells cultured in vitro and from the syngeneic
tumors. We found that the level of MCT4 in TC-1 tumors
was increased significantly compared to the basal expression
levels detected in lysates of cultured TC-1 cells (Figures 7D).
The result suggests that MCT4 expression by the epithelial
cells is sufficient to support tumor growth in this syngeneic
model.
DISCUSSION
MCT4 expression in cancers such as HNSCC, breast cancer,
melanoma, and hepatocellular carcinoma has been associated
with a poor prognosis (5, 26–28). In patient tumors, MCT4
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FIGURE 6 | Evaluation of peri-lesional macrophages in wild type and MCT4−/− tumors. Immunofluorescence staining for F4/80 (green) and MCT4 (red) and dapi
nuclear staining (blue) in wild type and MCT4−/− tongue frozen sections at 23 weeks of 4NQO treatment (A–F) scale bar: 20µm. F4/80 staining of frozen sections in
untreated tongues and at 14 and 23 weeks 4NQO treatment in wild type and MCT4−/− animals (G–L) Scale bar: 20µm. Quantification of F4/80 positive
macrophages in tongue sections. Involved areas represent regions identified by nuclear atypia and/or other signs of epithelial transformation, whereas non-involved
areas did not display these features within the same section (n = 3 for untreated, n= 8 for 14 weeks, n= 4 for 23 weeks per group) (M). Quantification of total
monocytes (N) in peripheral blood (n= 5–6 per group). *P < 0.05.
has been detected in cancer cells, cancer associated fibroblasts
(CAFs) as well as tumor associated macrophages (TAMs) where
it supports tumor growth (17), angiogenesis (29), and metastasis
(30) (Figure 1). In the current study, we used the well-established
4NQOmodel of carcinogenesis to induce OSCC in wild type and
MCT4−/− mice, with the goal of determining whether MCT4
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FIGURE 7 | MCT4 expression in syngeneic tumor cells is sufficient for tumor growth. Growth curve of TC-1 tumors in MCT4−/− and wild type mice (n = 10 per
group) (A) and average tumor weight at sacrifice (B). Quantification of total monocytes in peripheral blood of wild type and MCT4−/− animals before and after
transplantation (n = 5 per group) (C). Western blot analysis of lysates prepared from TC-1 cancer cells in vitro and TC-1 tumors grown in MCT4−/− and wild type
mice for MCT1 and MCT4 using GRB2 as a loading control (D).
is a driver or marker of OSCC progression. Our findings show
that in the absence of MCT4, tumor burden, and invasiveness is
reduced.
Growth and metastasis of cancer cells is supported by CAFs
and TAMs present in the tumor ecosystem. The use of 4NQO in
the drinking water to induce OSCC has several advantages over
syngeneic models. Chemical induction of OSCC results in tumor
formation in the normal ecosystem so the development and
progression to invasive cancer more closely mimics what is seen
in human patients (23). Models using transplantable OSCC cell
lines do not recapitulate the epithelial and stromal interactions
since the cells are injected into the flank of the mouse between
the hypodermis and skeletal muscles. This region lacks the
capillary bed and stroma found in the lamina propria of epithelial
tumors. The 4NQO model recapitulates histological features and
metabolic reprogramming observed in patient samples of OSCC
and thus provides a valuable model to investigate in vivo the
contribution of MCT4 to the development and progression of
OSCC.
In 4NQO treated animals, the cancer originates from the
highly proliferative cells found in the basal cell layer of
the stratified squamous epithelium covering the tongue (31).
4NQO treatment causes mutagenesis and oxidative stress in
these cells, which in turn translates in the dysregulation of
key transcription factors such as NF-kB (32) and Hif1α (33).
The cross-talk between the two transcription factors leads to
the activation of glycolysis (34, 35) through transcription of
glycolytic genes including MCT4 (36), glucose transporter 1
(GLUT1), hexokinase (HK), lactate dehydrogenase A (LDHA),
and genes regulating cell proliferative pathways. In the current
study, MCT4 was not detected in epithelium or stroma of the
untreated tongue but was detected focally in the basal and
suprabasal layers of the epithelium in tongues of wild type mice
treated with 4NQO (Figures 4A,B). The MCT4−/− mice treated
with 4NQO also developed dysplastic lesions and carcinomas
in situ (CIS) similarly to the wild type mice, demonstrating
that MCT4 is not necessary for the induction of non-invasive
OSCC. Our findings indicate that the early increase in MCT4
expression results from a global reprogramming of the epithelial
cells undergoing oncogenic transformation. When we analyzed
MCT4 expression in more severe and extensive lesions such as
carcinomas in situ, we found that MCT4 was often expressed
in a central compartment of the lesions (Figures 4E,F), which
may correspond with hypoxic areas. This centralized pattern
of expression replicates what has been documented in human
OSCC (5). Future studies will be needed to confirm if this pattern
correlates with regions of hypoxia. Large in situ lesions were
not found in tongues from MCT4−/− mice treated with 4NQO
since these epithelial cells cannot shift their metabolism toward
a hyperglycolytic state. It has been shown that inhibition of the
lactate transport has a negative effect on cell proliferation (17, 37).
The intracellular accumulation of lactate slows the glycolytic
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flux by directly inhibiting hexokinase and phosphofructokinase
(38) and by decreasing the NAD+/NADH ratio. In addition,
the decrease in glycolytic intermediates affects the production of
other metabolites necessary for cell proliferation. The inhibition
of MCT4 also leads to the acidification of the cytosol, which
can inhibit cell proliferation through the mTOR pathway
(39). In sum, future studies will need to be conducted to
determine the mechanism by which loss of MCT4 reduces tumor
aggressiveness.
The current study showed that MCT4−/− mice developed
fewer and smaller invasive carcinomas, more often they
developedmicro-invasive lesions. Additional studies are required
to establish the contribution of MCT4 to microinvasive
oral squamous cell tumors. The data suggest that the lack
of MCT4 prevents the progression of early microinvasive
lesions to full invasive, arresting the tumors in a less
aggressive form. In the wild type invasive lesions, MCT4 was
expressed in both epithelial cells and in stroma (Figures 4G,H).
In wild type mice expression of MCT4 facilitates lactate
eﬄux and acidification of the microenvironment promoting
invasiveness and metastasis. We and others have previously
shown that MCT4 is important for cancer cell migration
through interaction with beta 1 integrin (6, 40, 41) and it
has been shown that lactate in the microenvironment induce
angiogenesis (42), contributing to the progression of the
disease.
We have shown that in human samples of HNSCC, CD163
positive macrophages also express MCT4 (Figures 1D,E). In
the 4NQO treated animals we found macrophages in the
peri-lesional areas as early as 14 weeks of treatment and
these F4/80 positive cells expressed MCT4 (Figures 6A–C). In
the MCT4−/− animals, the number of macrophages noted
in the tumor microenvironment is lower compared to the
wild type (Figure 6M) suggesting that MCT4 in either one
of the compartments, or in both of them, has an effect
on the macrophage population. MCT4 is usually associated
with a higher glycolytic flux, therefore TAMs may have a
glycolytic metabolism as suggested by Liu et al. (43). It has
also been reported that bone marrow derived macrophages
(BMDM) knock down of MCT4 reduced the production
of cytokines after LPS stimulation (12), indicating that the
F4/80 cells in the tumor microenvironment of the MCT4−/−
animals may be compromised. Macrophages are recruited
to the tumor invasive edge by chemoattractants released by
the cancer cells. The recruited immune cells promote the
migration and invasion of the cancer by secreting factors
for the remodeling of the extracellular matrix (44). The
observation that fewer macrophages were present in the stroma
of the MCT4−/− tongues suggest that there was a failure
of the tumor to release sufficient levels of chemokines and
cytokines required to recruit monocytes from circulation. This
conclusion was supported by our analysis of the peripheral
blood from 4NQO treated MCT4−/− mice which showed
an increase in total monocytes in circulation (Figure 6N).
The circulating monocytes were the same in wild type and
MCT4−/− mice after TC-1 syngeneic tumors implantation and
the tumors expressed MCT4 independently of the genotype of
the host. This supports the idea that MCT4 expression in the
epithelium is necessary for the recruitment of macrophages to
the tumor microenvironment from the circulation (Figure 7)
but future studies will need to determine the contribution
of MCT4 expression in TC-1 cells to syngeneic tumor
growth.
MCT1 and MCT4 require the accessory protein CD147 for
maturation and trafficking to the plasma membrane. CD147 is
constitutively expressed and is stabilized through its interaction
with MCT1 and MCT4 (45). Consistently, we and others have
used in vitro and in vivo techniques to show that ablation of
any of these proteins (MCTs or CD147) causes the degradation
of the entire complex. Conversely, the increase in MCT1
and/or MCT4 in OSCC results in the obligatory increase
in CD147. In 4NQO-treated wild type and MCT4−/− mice,
MCT1 expression increased in dysplastic areas. The invasive
lesions also showed persistent expression of MCT1 (Figure 5).
It has been reported that increased expression of CD147 (also
known as EMMPRIN and basigin) is associated with poor
outcomes in OSCC (8). The use of drugs targeting CD147
in cancer has been explored (39) and the use of anti-CD147
antibodies resulted in reduced growth of OSCC xenografts (40).
Silencing CD147 or using drugs that target CD147 impact
the expression or activity of MCT1 and MCT4, supporting
the idea that targeting these transporters in patients with
OSCC could slow the development and progression of the
disease.
This study showed thatMCT4 is an early marker of OSCC and
that MCT4−/− mice had fewer lesions and less invasive cancer.
MCT4 could provide a viable target for drug therapy to slow
progression and aggressiveness in OSCC.
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